Lizzo has Thoughts: First Untitled Letter for Promotional Activities in a Yearwass
FDA Law Blog
JUNE 13, 2023
Wasserstein & Dara Katcher Levy — After about a year without any untitled letters from OPDP, Xeris Pharmaceuticals received an untitled letter for their promotion for Recorlev (levoketoconazole) for misleading safety and efficacy claims. By Jeffrey N.
Let's personalize your content